Roche lifts 2024 profit guidance on strong drug sales
First-half operating profit growth beats analyst estimates
Revenue from eye drug Vabysmo nearly doubles, beats estimates
Expects close to 10% adjusted profit growth, up vs previous
Shares traded near 1-year high earlier on Thursday
Adds details on eye drug in paragraphs 5 and 7, details on CEO's strategy in last two paragraphs
By Ludwig Burger
FRANKFURT, July 25 (Reuters) -Roche ROG.S on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye medicine Vabysmo.
The Swiss drugmaker said it expects growth in adjusted earnings in the "high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023, up from previous estimates of "mid single-digit" percentage growth.
Shares were up 2.4% in morning trading, after earlier rising as much as 4% to a one-year high.
First-half adjusted operating profit gained 4% to 11.3 billion Swiss francs ($12.8 billion), the family-controlled drugmaker said on Thursday, beating analysts' consensus estimate of 10.5 billion, based on LSEG data.
Revenue from Vabysmo, used to treat a common form of blindness in the elderly, almost doubled to 1.8 billion francs, beating market expectations.
Its European peers AstraZeneca AZN.L and Sanofi SASY.PA also raised their profit forecasts on Thursday, helped by strong growth of key drugs.
"There is no slowing down at all in the momentum that we see with Vabysmo," CEO Thomas Schinecker said in a media call.
A factor setting Vabysmo apart in its use for the disease known as wet macular degeneration was its ability to reduce fluid leaking into the back of the eye, he said.
Roche competes with Bayer BAYGn.DE and partner Regeneron REGN.O and their more established eye drug Eylea.
Breast cancer drug Phesgo, with sales up 60% at almost 800 million francs, also beat market expectations.
CEO Schinecker is pursuing a variety of therapeutic fields to offset falling oncology sales, setting a high deal pace.
The group suffered major drug trial setbacks in Alzheimer's and cancer immunotherapy in 2022.
Schinecker said he had cut 25% of the group's drug development pipeline to focus on the most promising projects since he took the helm last year.
($1 = 0.8830 Swiss francs)
Reporting by Ludwig Burger; Editing by Miranda Murray and Bernadette Baum
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
